Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin

Cerda A.; Genvigir F.D.V.; Arazi S.S.; Hirata M.H.; Dorea E.L.; Bernik M.M.S.; Bertolami M.C.; Faludi A.A.; Hirata R.D.C.

Abstract

Background: The SR-BI is a key component on the cholesterol metabolism. Polymorphisms in the SR-BI gene (SCARB1) were related with variations on plasma lipoprotein profile and other risk factors for cardiovascular disease. We tested the relationship of 3 SCARB1 single nucleotide polymorphisms (SNPs) with hypercholesterolemia in a Brazilian population and whether these variants can influence lipid-lowering response to atorvastatin. Methods: c.4G>A, c.726+54C>T and c.1050C>T SNPs and serum concentrations of lipid and apolipoproteins were evaluated in 147 hypercholesterolemic (HC) and 185 normolipidemic (NL) unrelated Brazilian subjects. HC patients were treated with atorvastatin (10. mg/day/4. weeks). Results: Frequencies of SCARB1 polymorphisms were similar between the HC and NL groups (p>0.05). The T allele for c.726+54C>T was associated with higher LDL-c in NL and with higher apoB and apoB/apoAI in HC (p<0.05). HC individuals carrying c.1050C allele carriers (CC and CT genotypes) had lower change of total cholesterol, LDL-c, apoB and apoB/apoAI ratio (p<0.05) than the TT genotype carriers in response to atorvastatin. Conclusion: The SCARB1 polymorphisms are related with variations in serum lipids in the Brazilian population and c.1050C>T SNP is associated with lipid-lowering atorvastatin response. © 2010 Elsevier B.V.

Más información

Título según SCOPUS: Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin
Título de la Revista: CLINICA CHIMICA ACTA
Volumen: 411
Número: 2015-10-09
Editorial: ELSEVIER SCIENCE BV
Fecha de publicación: 2010
Página de inicio: 631
Página final: 637
Idioma: English
DOI:

10.1016/j.cca.2010.01.002

Notas: SCOPUS